Flow Neuroscience, a small Swedish firm treating melancholy with brain-stimulating headsets, launched early information on Monday displaying that its system relieved depressive signs in medical trials.
The corporate has not but formally written up the info for a journal. However Stream leaders have included the info in an utility for Meals and Drug Administration approval and supplied STAT with topline information forward of releasing them publicly. If the trial strategies and outcomes maintain up underneath the FDA’s scrutiny, it could be the primary system of its form authorised to deal with melancholy in the US. Stream already sells its gadgets over-the-counter in Europe, the place it obtained regulatory approval in 2019.
“I’m very intrigued and hopeful, however on the identical time I’m slightly bit skeptical and need to see all these particulars,” stated Mark George, a psychiatry professor on the Medical College of South Carolina who was not concerned with the trial.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED